Roquefort Investments PLC (ROQ) AI Stock Analysis

• Market Cap: £1.68M
• Dividend Yield: N/A
• Average Volume (3M): 2.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 163,726,290
• 10 Day Avg. Volume: 1,674,162
• 30 Day Avg. Volume: 2,613,232
• PEG Ratio: 0.12
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 1.50 p ▲(25.00% Upside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.

Roquefort Investments PLC Business Overview & Revenue Model

Company Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

How the Company Makes Money

null

Roquefort Investments PLC Financial Statement Overview

Summary

Early-stage, pre-commercial profile with volatile/near-zero revenue and persistent losses. Cash flow remains negative (ongoing burn), partially offset by a relatively supportive balance sheet with low leverage despite declining equity over time.

Income Statement

The company is still pre-commercial with highly inconsistent revenue (2023: 200k; 2024: 0, a -100% decline). Losses remain persistent, though 2024 showed some improvement versus 2023 (net loss narrowed to -972k from -1.74m; operating loss also improved). Profitability is structurally weak with negative gross profit in 2024 and no sustained margin profile, indicating the business is not yet operating at scale.

Balance Sheet

Leverage is modest: 2024 total debt is ~400k against ~4.89m of equity (low debt-to-equity ~0.08), which supports financial flexibility. However, equity has declined over time (from ~7.21m in 2022 to ~4.89m in 2024), consistent with ongoing losses and dilution/consumption of capital. Returns on equity are meaningfully negative, reflecting that shareholders’ capital is not currently generating profits.

Cash Flow

Cash burn is ongoing, with operating and free cash flow negative every year shown (2024 operating/free cash flow about -784k). The burn rate improved materially in 2024 versus 2023 (operating cash outflow reduced from ~-1.73m), but free cash flow growth is still negative year-over-year in 2024. Cash generation does not yet support the income statement economics, and funding needs likely remain a key risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	200.00K	0.00	719.00
Gross Profit	-2.70K	-16.00K	200.00K	0.00	-9.35K
EBITDA	-926.73K	-1.11M	-1.93M	0.00	-352.40K
Net Income	-882.45K	-971.80K	-1.74M	-1.62M	-917.43K
Balance Sheet
Total Assets	5.66M	5.75M	6.09M	7.77M	4.56M
Cash, Cash Equivalents and Short-Term Investments	182.92K	337.11K	537.32K	2.32M	899.72K
Total Debt	383.65K	400.09K	0.00	0.00	0.00
Total Liabilities	909.12K	861.73K	589.02K	561.58K	477.43K
Stockholders Equity	4.75M	4.89M	5.50M	7.21M	4.08M
Cash Flow
Free Cash Flow	-645.62K	-783.73K	-1.79M	-1.58M	-2.62M
Operating Cash Flow	-588.75K	-783.73K	-1.73M	-1.58M	-2.62M
Investing Cash Flow	-57.06K	0.00	-52.57K	-103.48K	-1.11M
Financing Cash Flow	236.00K	584.91K	-58.00	3.10M	4.63M

Roquefort Investments PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRTC	55 Neutral	£293.63M	-2.25	12.82%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ROQ	44 Neutral	£1.68M	-0.94	-18.71%	―	―	―
SAR	44 Neutral	£21.40M	-3.13	-202.14%	―	―	23.76%
FAB	44 Neutral	£15.63M	-9.67	-210.32%	―	-11.43%	23.40%
CIZ	43 Neutral	£5.95M	-4,173.96	-433.59%	―	―	―
AVCT	42 Neutral	£301.81M	-1.74	-361.23%	―	―	―

Roquefort Investments PLC Corporate Events

Roquefort Therapeutics to buy AO-252 licence, raise £8.5m and move to AIM

Roquefort Therapeutics has agreed to acquire the exclusive worldwide licence to AO-252, a clinical-stage, orally administered, brain-penetrant small molecule inhibitor of TACC3 from Coiled Therapeutics Inc. The deal, valued at £31.875 million in shares, will transform the business into a clinical-stage oncology company with a portfolio including AO-252, now in a U.S. Phase I trial for advanced solid tumours, and an existing STAT-6 programme being evaluated for clinical development.

Alongside the acquisition, the company is raising £8.5 million via a conditional placing and subscription at 10 pence per share, with senior leaders participating and net proceeds of about £7.7 million earmarked to advance AO-252 through key clinical milestones in 2026–27 and provide working capital. Roquefort will cancel its Main Market listing, seek admission of its enlarged share capital to AIM, rebrand as Coiled Therapeutics plc, refresh its board, and position itself to tap strong pharma interest in precision oncology, particularly prostate and ovarian cancer therapies.

The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.

Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM

Roquefort Therapeutics plans to acquire worldwide exclusive rights to AO-252, a TACC3-targeting oncology drug candidate from Coiled Therapeutics and A2A Pharmaceuticals, while completing an associated equity fundraise and preparing documentation for admission to the London Stock Exchange’s AIM market. The company has formally initiated the process to delist its ordinary shares from the FCA’s Official List and the London Stock Exchange Main Market, with AIM readmission and completion of the AO-252 transaction expected to follow, signalling a strategic shift towards a growth-focused market segment and an expanded oncology pipeline.

Coiled Therapeutics, which holds the AO-252 rights, has advanced the brain-penetrant small molecule through pre-clinical work, IND approval and into an active Phase I trial in the U.S. for patients whose cancers have progressed on other treatments. A2A Pharma, Coiled’s parent and an AI-driven drug discovery company, has a track record of spinning out oncology assets, underscoring the potential strategic value of AO-252 for Roquefort’s future development plans.

The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.

Roquefort Therapeutics Flags New Broker Research on Coiled and A2A Deal

Roquefort Therapeutics has announced that its broker, SP Angel Corporate Finance, has published a new research note analysing the company’s proposed transaction with clinical-stage oncology firm Coiled Therapeutics and AI-driven drug discovery specialist A2A Pharmaceuticals. The note, now available via Roquefort’s website, is expected to give investors further insight into the strategic rationale for the deal, which links Roquefort to Coiled’s brain-penetrant cancer candidate AO-252 already in Phase I trials, and to A2A’s generative AI-enabled SCULPT platform and proven spin-out model, potentially strengthening Roquefort’s position in oncology drug development and long-term value creation.

The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.